BCMA-TEA-VVNEV

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameBCMA-TEA-VVNEV

Drug Alias NameAnti-CD3/anti-BCMA bispecific T-cell engager (Icell Kealex Therapeutics)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Oncolytic virus

Mechanisms of ActionCD3 T-cell engagersAnti-BCMA

TargetsT cell surface glycoprotein CD3B-cell maturation protein

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesN/A

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A